Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

25 Apr 2024

CEO Paul Hudson says that the French major will continue to progress early-stage cancer projects despite jettisoning some oncology programs in favor of reallocating much of its research budget to immunology.

Sanofi's shifting of R&D resources away from cancer to cement its industry leadership in immunology and inflammation is a sensible move but the company will continue to advance some interesting early-stage oncology projects that could become first and/or best-in-class medicines.

This was the message from CEO Paul Hudson as he unveiled Sanofi's first-quarter figures on 25 April. The results came after a busy couple of weeks of restructuring at the French drugmaker which include plans to divest Amunix Pharmaceuticals, Inc., an immuno-oncology specialist acquired in 2022 for $1bn, the closure of Dutch natural killer (NK) cell therapy subsidiary Kiadis Pharma NV and a rejigged collaboration with IGM Biosciences, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Transient FY26 For Syngene But Momentum In China +1 Projects

02 May 2025

• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.